FDA Approves RYZUMVI for Presbyopia Treatment in Adults

The U.S. Food and Drug Administration (FDA) has granted approval for RYZUMVI (phentolamine ophthalmic solution 0.75%) to treat presbyopia in adults. This marks an expanded indication for the drug, which was previously approved for pharmacologically-induced mydriasis. The approval is supported by positive outcomes from the pivotal Phase 3 VEGA-2 and VEGA-3 clinical trials. Viatris, the company that received the approval, is actively seeking a commercial partner for the drug's distribution in the U.S.